Abstract
Schwann cells are critically important for tissue repair, axonal regrowth and remyelination following injury to peripheral nerves. The absence of Schwann cells or an equivalent cell type in the central nervous system (CNS) may limit the regeneration capacity of the CNS. Mesenchymal stem cells (MSCs) have therefore been investigated for their potential to be induced to develop a Schwann cell phenotype. The methods for derivation of Schwann cell-like cells from MSCs and the benefits and limitations of each of these methods are presented in this review. Issues related to instability of the derived Schwann cell phenotype, apoptosis of derived cells in transplants, and the inability to predict with confidence how the cells will behave after transplantation are discussed. Finally, we suggest the need for further elucidation of the biology of Schwann cell differentiation and the signals for their derivation from MSC, in order to resolve these obstacles and to enable transplantation of MSC-derived Schwann cells as a therapeutic strategy in CNS injury.
Keywords: Mesenchymal stem cells, Schwann cells, spinal cord injury, two-step induction, stem cell co-culture, peripheral nervous system, central nervous system, embryonic stem cells, induced pluripotent stem cells, neural stem cels, olfactory ensheathing cells
CNS & Neurological Disorders - Drug Targets
Title: Derivation of Clinically Applicable Schwann Cells from Bone Marrow Stromal Cells for Neural Repair and Regeneration
Volume: 10 Issue: 4
Author(s): Sa Cai, Graham K.H. Shea, Alex Y.P. Tsui, Ying-Shing Chan and Daisy K.Y. Shum
Affiliation:
Keywords: Mesenchymal stem cells, Schwann cells, spinal cord injury, two-step induction, stem cell co-culture, peripheral nervous system, central nervous system, embryonic stem cells, induced pluripotent stem cells, neural stem cels, olfactory ensheathing cells
Abstract: Schwann cells are critically important for tissue repair, axonal regrowth and remyelination following injury to peripheral nerves. The absence of Schwann cells or an equivalent cell type in the central nervous system (CNS) may limit the regeneration capacity of the CNS. Mesenchymal stem cells (MSCs) have therefore been investigated for their potential to be induced to develop a Schwann cell phenotype. The methods for derivation of Schwann cell-like cells from MSCs and the benefits and limitations of each of these methods are presented in this review. Issues related to instability of the derived Schwann cell phenotype, apoptosis of derived cells in transplants, and the inability to predict with confidence how the cells will behave after transplantation are discussed. Finally, we suggest the need for further elucidation of the biology of Schwann cell differentiation and the signals for their derivation from MSC, in order to resolve these obstacles and to enable transplantation of MSC-derived Schwann cells as a therapeutic strategy in CNS injury.
Export Options
About this article
Cite this article as:
Cai Sa, K.H. Shea Graham, Y.P. Tsui Alex, Chan Ying-Shing and K.Y. Shum Daisy, Derivation of Clinically Applicable Schwann Cells from Bone Marrow Stromal Cells for Neural Repair and Regeneration, CNS & Neurological Disorders - Drug Targets 2011; 10 (4) . https://dx.doi.org/10.2174/187152711795563930
DOI https://dx.doi.org/10.2174/187152711795563930 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Polypeptide Toxins from Animal Venoms
Recent Patents on DNA & Gene Sequences Immunophilins in Nervous System Degeneration and Regeneration
Current Topics in Medicinal Chemistry Role of Fractalkine (CX3CL1) in Regulating Neuron-Microglia Interactions: Development of Viral-Based CX3CR1 Antagonists
Current Alzheimer Research Prevention and Treatment of Alzheimer Disease and Aging: Antioxidants
Mini-Reviews in Medicinal Chemistry AMPK Function in Aging Process
Current Drug Targets A Scientometrics Analysis and Visualization of Depressive Disorder
Current Neuropharmacology Therapeutic Strategies in Autoimmune Diseases by Interfering with Leukocyte Endothelium Interaction
Current Pharmaceutical Design Astrocytes: New Targets for the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Non Pharmacological Strategies to Promote Spinal Cord Regeneration: A View on Some Individual or Combined Approaches
Current Pharmaceutical Design Alternative Routes of Administration of the Neuroprotective Pituitary Adenylate Cyclase Activating Polypeptide
Current Pharmaceutical Design Development of Proteinase-Activated Receptor 1 Antagonists as Therapeutic Agents for Thrombosis, Restenosis and Inflammatory Diseases
Current Pharmaceutical Design Drugs and Aggression
Recent Patents on CNS Drug Discovery (Discontinued) Redox Processes in Neurodegenerative Disease Involving Reactive Oxygen Species
Current Neuropharmacology Perspectives on the Development of Antioxidant Antiepileptogenic Agents
Mini-Reviews in Medicinal Chemistry Cytokine Transport Across the Injured Blood-Spinal Cord Barrier
Current Pharmaceutical Design Traumatic Spinal Cord Injury Alters Angiogenic Factors and TGF-Beta1 that may Affect Vascular Recovery
Current Neurovascular Research Biological Implications of Oxidation and Unidirectional Chiral Inversion of D-amino Acids
Current Drug Metabolism Increased Neuronal Injury in Transgenic Mice with Neuronal Overexpression of Human Cyclooxygenase-2 is reversed by Hypothermia and Rofecoxib Treatment
Current Neurovascular Research Antioxidant Therapy in Alzheimers Disease: Theory and Practice
Mini-Reviews in Medicinal Chemistry Innate Immune Surveillance in the Central Nervous System Following Legionella pneumophila Infection
CNS & Neurological Disorders - Drug Targets